Skip to main content
Passa alla visualizzazione normale.

GIUSEPPE CABIBBO

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

  • Authors: Stefanini, Benedetta; Bucci, Laura; Santi, Valentina; Reggidori, Nicola; Rampoldi, Davide; Lani, Lorenzo; Granito, Alessandro; Sangiovanni, Angelo; Cabibbo, Giuseppe; Farinati, Fabio; Campani, Claudia; Foschi, Francesco Giuseppe; Svegliati-Baroni, Gianluca; Raimondo, Giovanni; Gasbarrini, Antonio; Mega, Andrea; Biasini, Elisabetta; Sacco, Rodolfo; Morisco, Filomena; Caturelli, Eugenio; Vidili, Gianpaolo; Azzaroli, Francesco; Giannini, Edoardo G; Rapaccini, Gian Ludovico; Brunetto, Maurizia Rossana; Masotto, Alberto; Nardone, Gerardo; Di Marco, Mariella; Magalotti, Donatella; Trevisani, Franco
  • Publication year: 2022
  • Type: Articolo in rivista
  • OA Link: http://hdl.handle.net/10447/579135

Abstract

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (29%) patients were qualified for atezolizumab-bevacizumab therapy. The main exclusion causes were Child-Pugh class and Performance Status. Adopting the more permissive inclusion criteria of SHARP trial, 535 patients became eligible. The median overall survival of tyrosine-kinase inhibitors patients was 14.9 months, longer in eligible patients than in their counterpart due to better baseline liver function and oncological features.Conclusion: Real-world data indicate that less than one-third of hepatocellular carcinoma patients treated with tyrosine-kinase inhibitors are potentially eligible to atezolizumab-bevacizumab according to the reg-istration trial criteria. These patients have a longer survival than the non-eligible ones. If the selection criteria of atezolizumab-bevacizumab trial are maintained in clinical practice, tyrosine-kinase inhibitors will remain the most used systemic therapy for hepatocellular carcinoma patients.(c) 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.